暫無數據
代碼股票名稱
最新價漲跌額升跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日升跌幅10日升跌幅20日升跌幅60日升跌幅120日升跌幅250日升跌幅年初至今升跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
自選模擬交易
美股市場個股詳情
GLTO Galecto
- 7.000
- -0.080-1.13%
收盤價 11/12 16:00 (美東)
- 7.000
- 0.0000.00%
盤後 16:04 (美東)
921.89萬總市值-366市盈率TTM
7.050最高價6.810最低價1.18萬股成交量7.050今開7.080昨收8.18萬成交額0.97%換手率虧損市盈率(靜)131.70萬總股本23.50052周最高0.44市淨率849.17萬流通值6.50052周最低--股息TTM121.31萬流通股449.750歷史最高--股息率TTM3.39%振幅6.500歷史最低6.928平均價1股每手
盤後分時
- 5日
- 日線
- 周線
- 月線
- 季K
- 年K
資金分布
單位: --
資金流向
實時日周月
暫無數據
新聞
galecto預計其現金、現金等價物和投資將足以支持至少未來十二個月的營業費用和資本需求>GLTO
galecto預計其現金、現金等價物和投資將足以支付營業費用和至少未來12個月的資本需求
截至9月30日，galecto的現金、現金等價物和投資爲1970萬美元 >GLTO
截至9月30日，galecto的現金、現金等價物和投資達1970萬美元
快訊 | galecto報告2024年第三季度財務業績
Galecto第三季度每股虧損3.39美元>GLTO
galecto第三季虧損每股3.39美元 >
galecto第三季度虧損388萬美元，大於GLTO
Galecto第三季度虧損388萬美元 >
新聞發佈：galecto報告2024年第三季度財務結果
galecto報告2024年第三季度財務業績 - 完成戰略審查，專注於腫瘤學和嚴重肝病 - 宣佈收購全球對BRm-1420的權利，這是一種雙重ENL-
評論
$Galecto (GLTO.US)$
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
• Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211
• Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)
• BRM-1420 has the potential for enhanced clinical effectivenes...
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
• Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211
• Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)
• BRM-1420 has the potential for enhanced clinical effectivenes...
![[瞓]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "瞓"){kind=small}
$Galecto (GLTO.US)$
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various can...
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various can...
2
閱讀更多
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
升跌幅
暫無數據